GlycoMimetics (GLYC)
(Delayed Data from NSDQ)
$0.27 USD
-0.03 (-10.54%)
Updated May 10, 2024 03:59 PM ET
After-Market: $0.26 -0.01 (-2.48%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum F VGM
GlycoMimetics (GLYC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$0.75 | $1.00 | $0.50 | 150.00% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for GlycoMimetics comes to $0.75. The forecasts range from a low of $0.50 to a high of $1.00. The average price target represents an increase of 150% from the last closing price of $0.30.
Analyst Price Targets (2 )
Broker Rating
GlycoMimetics currently has an average brokerage recommendation (ABR) of 2.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, two are Strong Buy, representing 50% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/6/2024 | H.C. Wainwright & Co. | Edward White | Strong Buy | Hold |
5/6/2024 | Capital One Securities | Naureen Quibria | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 4 |
Average Target Price | $0.75 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 94 of 252 |
Current Quarter EPS Est: | -0.15 |